SeekingAlpha  7 hrs ago  Comment 
By Peter Geschek: Palbociclib update Early approval hopes of palbociclib, based on Phase 2 data, are fading. At the annual meeting of the American Association for Cancer Research in San Diego, Pfizer (PFE) presented details of the Phase 2...
The Hindu Business Line  Apr 12  Comment 
Research finds ban on the painkiller has slowed down the decline in numbers
Wall Street Journal  Apr 10  Comment 
Competition authorities raided the French offices of Roche Holding AG and Novartis AG earlier this week, part of an investigation into alleged price fixing of an eye treatment.
Financial Times  Apr 10  Comment 
FiercePharma  Apr 10  Comment 
With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.
FierceBiotech  Apr 9  Comment 
BVCF, a Shanghai-based life sciences investor, has closed its third fund with $188 million to back upstart biotechs on both sides of the Pacific focused on the booming Asian market.
Forbes  Apr 9  Comment 
Patient, physicians and payers are all demanding that new medicines deliver value over older or current therapies. Drug companies are setting out to do just that. However, running the types of studies that Novartis and GSK did are not trivial, are...
Wall Street Journal  Apr 9  Comment 
Novartis is promoting a veteran manager to run its Alcon eye-care division, and has hired another executive to head its Sandoz generics business, as it re-evaluates its operations.
Forbes  Apr 8  Comment 
One of the most exciting developments in cancer research is the development of techniques to genetically re-engineer a patient's own immune cells to destroy tumors. Several companies are racing to commercialize this technology. In the lead are...
FierceBiotech  Apr 8  Comment 
Versant Ventures is gambling $12 million on a spinoff of the University of Basel with an in-house drug program that is angling to come up behind one of Novartis's top mid-stage cancer assets.
DailyFinance  Apr 7  Comment 
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/07/14 -- Alios BioPharma, Inc., a biotechnology company developing proprietary therapeutics for respiratory viral diseases, today announced it has completed a $41 Million Series B financing. All...


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki